Introduction
Currently, Alpha-Fetoprotein (AFP) is used clinically as a biomarker for detecting liver cancer. However, even if abnormal AFP is detected in clinical practice, it can only represent that the liver is in an inflamed state and cannot be completely correct. Detect whether you have suffered from liver cancer. Therefore, for groups at high risk of liver cancer, it is still insufficient to rely solely on the test results of fetal serum protein A to determine whether you have suffered from liver cancer.
Features / strengths
The present invention utilizes intestinal microflora (from the following bacterial genera: Phascolarctobacterium, Lachnospira, Megasphaera, Streptococcus and Bifidobacterium. ) was combined with the current liver cancer biomarker fetal serum protein A to establish a marker. The accuracy of liver cancer diagnosis and prediction is expected to achieve higher sensitivity and specificity than a single type A fetal serum protein bioassay.
Specification in detail
Under development
Seek of partners for business cooperation
